neuroloop

Executive Summary

Neuroloop GmbH is a German medical device company pioneering a closed-loop implantable system for selective vagus nerve stimulation. Founded in 2017 as a spin-off from the University of Freiburg, the company aims to address unmet needs in functional neurosurgery, with an initial focus on blood pressure regulation. Its core technology is a specialized cuff electrode that precisely targets specific nerve fibers within the vagus nerve, potentially enabling more effective and safer neuromodulation. Currently at the pre-clinical stage, Neuroloop is advancing its device through animal studies and preparing for regulatory interactions. The company has not disclosed total funding or valuation, but its novel approach could capture significant market share in hypertension and other autonomic disorders if clinical validation succeeds. Key risks include the early stage of development, technical challenges in selective stimulation, and the need for substantial capital to fund clinical trials.

Upcoming Catalysts (preview)

• Q4 2026Completion of pivotal animal studies demonstrating safety and efficacy60% success
• Q1 2027Series A financing round to support first-in-human trials50% success
• Q3 2027First-in-human clinical trial initiation40% success